Heparin-derived supersulfated disaccharide inhibits allergic airway responses in sheep

Pulmonary Pharmacology & Therapeutics
Tahir AhmedW M Abraham

Abstract

The tetrasaccharide sequence of heparin oligosaccharides is the minimum chain length possessing anti-allergic activity, as the disaccharide fraction is inactive. Since sulfation pattern can modify the biological actions of heparin, we hypothesized that "supersulfation" of the inactive heparin disaccharide could confer anti-allergic activity to this molecule. To test this, we produced a supersulfated heparin disaccharide (Hep-SSD) and evaluated its anti-allergic activity in sheep with documented antigen-induced early and late airway responses (EAR and LAR) and airway hyperresponsiveness (AHR). Porcine intestinal heparin was depolymerized with nitrous acid, the disaccharide fraction separated by size exclusion chromatography, and then treated with pyridine-sulfur trioxide complex to yield Hep-SSD. Its chemical structure [IdoU2',3',4'S (1→4) AMan1,3,6S] was confirmed by HPLC, Mass Spectrometry and NMR analysis. Inhaled doses of 5 mg, 10 mg and 20 mg Hep-SSD produced inhibition of EAR (8%, 35% and 35%), LAR (50%, 80%, and 77%) and AHR (67%, 100% and 75%), respectively. A single oral dose of 2 mg/kg Hep-SSD given 90 min before challenge significantly inhibited EAR, LAR and AHR, but 1 mg/kg was ineffective. Multi dose oral treatment ...Continue Reading

References

Sep 7, 1976·Biochemistry·J E Shively, H E Conrad
Mar 1, 1992·The American Review of Respiratory Disease·T AhmedJ D'Brot
May 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·A K LarsenJ Folkman
Apr 1, 1985·Seminars in Thrombosis and Hemostasis·M J Bienkowski, H E Conrad
Jul 1, 1985·Journal of Cellular Physiology·J J CastellotM J Karnovsky
Nov 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·U LindahlI G Leder
Jul 1, 1994·Thrombosis Research·U LindahlL Kjellén
Jan 1, 1993·The American Review of Respiratory Disease·S D BowlerP S Lavercombe
Jul 8, 1993·The New England Journal of Medicine·T AhmedI Danta
Jun 1, 1996·American Journal of Respiratory and Critical Care Medicine·Z DiamantP J Sterk
Apr 8, 1999·American Journal of Respiratory and Critical Care Medicine·W M AbrahamP J Beck
Aug 3, 1999·American Journal of Respiratory and Critical Care Medicine·T AhmedI Danta
Jun 19, 2003·British Journal of Pharmacology·Rachel A BrownClive P Page
Jul 22, 2004·British Journal of Pharmacology·Harm MaarsinghHerman Meurs
Jun 15, 2005·Carbohydrate Research·János KuszmannSándor Boros
Oct 31, 2009·American Journal of Respiratory and Critical Care Medicine·Bruce E MaryanoffWilliam M Abraham
Oct 23, 2012·Pulmonary Pharmacology & Therapeutics·Tahir AhmedWilliam M Abraham

❮ Previous
Next ❯

Citations

Oct 5, 2017·Pharmaceuticals·Shifaza Mohamed, Deirdre R Coombe
Apr 25, 2019·International Journal of Molecular Sciences·Shravan Morla

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.